Sign up
Pharma Capital

Advanced Medical Solutions receives US regulatory approvals for two wound care products

The innovative dressings help prevent and treat infection and accelerate the healing
1533884667_shutterstock_170667932.jpg
The products are for post-operative use

Wound care specialist Advanced Medical Solutions Group PLC (LON:AMS) has received the green light from the US regulator for two new products.

The Food & Drug Administration granted premarket 510(k) approvals for the group's post-operative dressing and foam dressing.

"These most recent approvals strengthen our advanced wound care portfolio in the US and provide further significant products to support our OEM customers and end users,” said chief executive Chris Meredith.

“We are particularly pleased to be able to demonstrate the value of our R&D and regulatory capabilities which are a key pillar of our strategy to drive organic growth."

Ian_55ae0ddd437b7.jpg


Register here to be notified of future AMS Company articles
View full AMS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.